Dx & Vx（A180400）株式概要Dx & Vx Co, Ltd.は、主に韓国でバイオヘルスケア製品の開発・販売と分子遺伝学的検査サービスの提供を行っている。 詳細A180400 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間41.9%減少しました。 すべてのリスクチェックを見るA180400 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW483,546 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA483,546 investors already sharing narrativesYour Fair Value₩Current Price₩2.25k298.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-49b65b2016201920222025202620282031Revenue ₩65.1bEarnings ₩11.4bAdvancedSet Fair ValueView all narrativesDx & Vx Co., Ltd. 競合他社GC CellSymbol: KOSDAQ:A144510Market cap: ₩201.5bNKMAXSymbol: KOSDAQ:A182400Market cap: ₩172.7bKangstem BiotechSymbol: KOSDAQ:A217730Market cap: ₩198.9bHEM PharmaSymbol: KOSDAQ:A376270Market cap: ₩286.3b価格と性能株価の高値、安値、推移の概要Dx & Vx過去の株価現在の株価₩2,245.0052週高値₩5,360.0052週安値₩1,319.00ベータ-0.00811ヶ月の変化4.18%3ヶ月変化-52.74%1年変化14.78%3年間の変化-68.51%5年間の変化n/aIPOからの変化-53.62%最新ニュースお知らせ • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South KoreaNew Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.お知らせ • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct ListingNew Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).分析記事 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...最新情報をもっと見るRecent updatesお知らせ • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South KoreaNew Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.お知らせ • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct ListingNew Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).分析記事 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...New Risk • Nov 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -₩3.2b This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩88.4b market cap, or US$60.2m).分析記事 • Aug 20There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price RiseKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Dx...分析記事 • Aug 18We Think Dx & Vx (KOSDAQ:180400) Has A Fair Chunk Of DebtKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Some...New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩132.4b market cap, or US$95.9m).お知らせ • May 30Dx&Vx Accelerates Development of Universal COVID-19 VaccineDx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide. Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants. Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.お知らせ • Mar 12Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea分析記事 • Feb 14Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 32% LowerThe Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩65.0b market cap, or US$45.1m).分析記事 • Feb 12Is Dx & Vx (KOSDAQ:180400) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Dec 05Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 28%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩93.1b market cap, or US$66.7m).分析記事 • Oct 21Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price SlumpDx & Vx Co., Ltd. ( KOSDAQ:180400 ) shareholders that were waiting for something to happen have been dealt a blow with...お知らせ • Oct 04Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion.Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion on October 2, 2024. The consideration consists of 1.7 million common equity of Dx & Vx Co., Ltd. at a ratio of 0.290319 per common equity of Avixgen, Inc. The merger agreement is expected to signed on October 4, 2024. The expected completion of the transaction is December 17, 2024.New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩131.4b market cap, or US$98.6m).お知らせ • Sep 13Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion.Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,385,983 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 614,017 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Transaction Features: Rights OfferingNew Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩111.4b market cap, or US$83.4m).お知らせ • Jul 19DX&VX Is on Track and Accelerating the Development of Oral Obesity TreatmentDX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates. GLP-1 (glucagon-like peptide-1), an oral obesity treatment drug being developed by DX&VX, is a hormone that induces weight loss by suppressing appetite and increasing satiety to treat obesity. DX&VX researchers have developed organic compounds that can be taken orally once a day instead of through injections. While obesity treatment drug developers are conducting clinical trials for new oral GLP-1 organic compound drugs, the importance of this field is expanding day by day. To date, DX&VX has secured excellent candidate substances based on its AI-based innovative new drug design technology, and plans to submit patents for at least two more substances within this year. This research outcome is receiving significant attention from the industry and many pharmaceutical companies, both domestically and internationally, with some companies exploring the possibility of cooperation with DX&VX. Based on these achievements, DX&VX is expected to further accelerate the development of oral GLP-1 obesity treatments by utilizing various options such as early licensing out, global joint clinical trials, and research funding investment. As additional research results and patent applications continue, the obesity treatment drug being developed byDX&VX is expected to have stronger market competitiveness in the future.分析記事 • Jul 15Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% LowerUnfortunately for some shareholders, the Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has dived 39% in the last...分析記事 • May 31Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...New Risk • May 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩84.6b market cap, or US$61.5m).New Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 9.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩123.9b market cap, or US$90.8m).Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).分析記事 • Mar 18Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% HidingTo the annoyance of some shareholders, Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) shares are down a considerable 25% in the...分析記事 • Mar 08Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).New Risk • Jun 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).お知らせ • Jun 15Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investorsOn June 14, 2023, Dx & Vx Co., Ltd. closed the transaction.お知らせ • May 25Dx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, IncDx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, Inc. recently.お知らせ • May 17+ 1 more updateDxVx Appoints Kevin Kwon as New PresidentDxVx announced on May 16, 2023, the board of directors appointed Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. The new president, Kevin Kwon, holds a bachelor's and master's degree in applied bio-chemistry from Seoul National University, as well as a doctorate in management of technology from Korea University. He worked at the LG Chemical Biotech Research Institute and Regulatory Affairs (RA) Team in the LG Life Science. At Hanmi Pharm.Co.,Ltd, he served as the head of the global business division. He was a key person in global pharmaceutical business operations including global RA, overseas business development, overseas sales, clinical trials for new drug and licensing activities. In his career, he served as a joint professor at the Korea University Engineering Graduate School, an advisor for Korea Innovative Medicine Consortium (KimCo), an advisor for the formulation of bio similar regulations for the Ministry of Food and Drug Safety, a delegate for opening global markets at the Korea Health Industry Development Institute, and a professor for academic and business cooperation at Catholic University. Currently, he serves as a member of the special committee for global expansion at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. New president Kevin Kwon will be appointed as a board director from a shareholders' meeting. The former CEO, Sang Tae Park, has been nominated for the board director at Avixgen. In his new role, he intends to continue to make contributions to the company's growth by taking the lead in advancing the pipeline for new drugs and establishing a presence in the North American market.Board Change • Apr 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.株主還元A180400KR BiotechsKR 市場7D2.5%-4.4%-2.3%1Y14.8%-14.5%97.1%株主還元を見る業界別リターン: A180400過去 1 年間で-14.5 % の収益を上げたKR Biotechs業界を上回りました。リターン対市場: A180400は、過去 1 年間で97.1 % のリターンを上げたKR市場を下回りました。価格変動Is A180400's price volatile compared to industry and market?A180400 volatilityA180400 Average Weekly Movement9.3%Biotechs Industry Average Movement11.5%Market Average Movement9.5%10% most volatile stocks in KR Market17.1%10% least volatile stocks in KR Market5.0%安定した株価: A180400 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A180400の 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200188Yong-Gu Leewww.dxvx.comLtd.は、主に韓国でバイオヘルスケア製品の開発・販売と分子遺伝学的検査サービスの提供を行っている。同社は、Ofmom Carefree、オート麦発酵食品、バイオクリーナーなどのヘルスケア製品、CLIDEX、精密診断、体外診断キットなどの診断製品、健康診断サービス、CDx開発サービス、医療データ、葬儀場運営サービスなどを提供している。呼吸器疾患用細菌ワクチン、黄斑変性症治療薬、アトピー性皮膚炎治療薬、眼精疲労治療薬、抗がん剤ワクチン、新規抗体医薬を提供。パイプラインには、経口小児用Covid19/インフルエンザワクチンであるVx製品、新規抗がん抗体医薬品、高度なmRNAワクチン開発技術を活用した抗体医薬品、呼吸器疾患用細菌ワクチン、肥満と診断をターゲットとした新薬などのVxマイクロバイオーム研究開発パイプライン、ROP技術を活用した抗がんワクチンであるOxford Vacmedix Vaccineなどがある。bereum、Bioapp、CORESTEMCHEMON、Genscript PROBIO、JOINTOWN PHARMACEUTICAL GROUP等と共同研究を行っている。旧社名は株式会社キャンサーロップで、2022年1月に株式会社Dx&Vxに社名変更した。同社は2001年に設立され、韓国ソウルに本社を置く。もっと見るDx & Vx Co., Ltd. 基礎のまとめDx & Vx の収益と売上を時価総額と比較するとどうか。A180400 基礎統計学時価総額₩220.97b収益（TTM）-₩29.38b売上高(TTM)₩28.48b7.8xP/Sレシオ-7.5xPER（株価収益率A180400 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A180400 損益計算書（TTM）収益₩28.48b売上原価₩26.19b売上総利益₩2.29bその他の費用₩31.67b収益-₩29.38b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-298.46グロス・マージン8.05%純利益率-103.14%有利子負債／自己資本比率16.1%A180400 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/25 20:28終値2026/07/24 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dx & Vx Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
New Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).
New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.
お知らせ • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct Listing
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).
分析記事 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
お知らせ • Mar 17Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026Dx & Vx Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
New Risk • Jan 20New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding).
New Risk • Dec 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩25b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years.
お知らせ • Dec 23Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering.Dx & Vx Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 49,210,000 Transaction Features: Subsequent Direct Listing
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩111.5b market cap, or US$75.4m).
分析記事 • Dec 18The Market Doesn't Like What It Sees From Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues YetDx & Vx Co., Ltd.'s ( KOSDAQ:180400 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
New Risk • Nov 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -₩3.2b This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Negative equity (-₩3.2b). Earnings have declined by 48% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩88.4b market cap, or US$60.2m).
分析記事 • Aug 20There's No Escaping Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Muted Revenues Despite A 28% Share Price RiseKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Dx...
分析記事 • Aug 18We Think Dx & Vx (KOSDAQ:180400) Has A Fair Chunk Of DebtKOSDAQ:A180400 1 Year Share Price vs Fair Value Explore Dx & Vx's Fair Values from the Community and select yours Some...
New Risk • Jul 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩132.4b market cap, or US$95.9m).
お知らせ • May 30Dx&Vx Accelerates Development of Universal COVID-19 VaccineDx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide. Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants. Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies.
お知らせ • Mar 12Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025Dx & Vx Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
分析記事 • Feb 14Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 32% LowerThe Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • Feb 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩65.0b market cap, or US$45.1m).
分析記事 • Feb 12Is Dx & Vx (KOSDAQ:180400) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Dec 05Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 28%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 25% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩93.1b market cap, or US$66.7m).
分析記事 • Oct 21Positive Sentiment Still Eludes Dx & Vx Co., Ltd. (KOSDAQ:180400) Following 27% Share Price SlumpDx & Vx Co., Ltd. ( KOSDAQ:180400 ) shareholders that were waiting for something to happen have been dealt a blow with...
お知らせ • Oct 04Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion.Dx & Vx Co., Ltd. (KOSDAQ:A180400) agreed to acquire remaining 37% stake in Avixgen, Inc. for KRW 4.7 billion on October 2, 2024. The consideration consists of 1.7 million common equity of Dx & Vx Co., Ltd. at a ratio of 0.290319 per common equity of Avixgen, Inc. The merger agreement is expected to signed on October 4, 2024. The expected completion of the transaction is December 17, 2024.
New Risk • Oct 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 63% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (63% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩131.4b market cap, or US$98.6m).
お知らせ • Sep 13Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion.Dx & Vx Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 42.37 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 18,385,983 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Security Name: Common Stock Security Type: Common Stock Securities Offered: 614,017 Price\Range: KRW 2230 Discount Per Security: KRW 44.6 Transaction Features: Rights Offering
New Risk • Aug 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩111.4b market cap, or US$83.4m).
お知らせ • Jul 19DX&VX Is on Track and Accelerating the Development of Oral Obesity TreatmentDX&VX, which is gaining attention for developing an oral GLP-1 obesity treatment. The company is accelerating the optimization of new drug candidates. GLP-1 (glucagon-like peptide-1), an oral obesity treatment drug being developed by DX&VX, is a hormone that induces weight loss by suppressing appetite and increasing satiety to treat obesity. DX&VX researchers have developed organic compounds that can be taken orally once a day instead of through injections. While obesity treatment drug developers are conducting clinical trials for new oral GLP-1 organic compound drugs, the importance of this field is expanding day by day. To date, DX&VX has secured excellent candidate substances based on its AI-based innovative new drug design technology, and plans to submit patents for at least two more substances within this year. This research outcome is receiving significant attention from the industry and many pharmaceutical companies, both domestically and internationally, with some companies exploring the possibility of cooperation with DX&VX. Based on these achievements, DX&VX is expected to further accelerate the development of oral GLP-1 obesity treatments by utilizing various options such as early licensing out, global joint clinical trials, and research funding investment. As additional research results and patent applications continue, the obesity treatment drug being developed byDX&VX is expected to have stronger market competitiveness in the future.
分析記事 • Jul 15Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% LowerUnfortunately for some shareholders, the Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has dived 39% in the last...
分析記事 • May 31Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%The Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • May 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩84.6b market cap, or US$61.5m).
New Risk • May 29New major risk - Revenue and earnings growthEarnings have declined by 9.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩18b free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (4.6% increase in shares outstanding). Market cap is less than US$100m (₩123.9b market cap, or US$90.8m).
Reported Earnings • Mar 23Full year 2023 earnings released: ₩929 loss per share (vs ₩47.45 loss in FY 2022)Full year 2023 results: ₩929 loss per share (further deteriorated from ₩47.45 loss in FY 2022). Revenue: ₩46.7b (up 45% from FY 2022). Net loss: ₩27.5b (loss widened ₩26.1b from FY 2022).
分析記事 • Mar 18Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% HidingTo the annoyance of some shareholders, Dx & Vx Co., Ltd. ( KOSDAQ:180400 ) shares are down a considerable 25% in the...
分析記事 • Mar 08Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Oct 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
New Risk • Jun 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
お知らせ • Jun 15Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investorsOn June 14, 2023, Dx & Vx Co., Ltd. closed the transaction.
お知らせ • May 25Dx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, IncDx & Vx Co., Ltd. (KOSDAQ:A180400) acquired Avixgen, Inc. recently.
お知らせ • May 17+ 1 more updateDxVx Appoints Kevin Kwon as New PresidentDxVx announced on May 16, 2023, the board of directors appointed Kevin Kwon, the former head of global business division at Hanmi Pharm.Co.,Ltd., as the new president. The new president, Kevin Kwon, holds a bachelor's and master's degree in applied bio-chemistry from Seoul National University, as well as a doctorate in management of technology from Korea University. He worked at the LG Chemical Biotech Research Institute and Regulatory Affairs (RA) Team in the LG Life Science. At Hanmi Pharm.Co.,Ltd, he served as the head of the global business division. He was a key person in global pharmaceutical business operations including global RA, overseas business development, overseas sales, clinical trials for new drug and licensing activities. In his career, he served as a joint professor at the Korea University Engineering Graduate School, an advisor for Korea Innovative Medicine Consortium (KimCo), an advisor for the formulation of bio similar regulations for the Ministry of Food and Drug Safety, a delegate for opening global markets at the Korea Health Industry Development Institute, and a professor for academic and business cooperation at Catholic University. Currently, he serves as a member of the special committee for global expansion at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. New president Kevin Kwon will be appointed as a board director from a shareholders' meeting. The former CEO, Sang Tae Park, has been nominated for the board director at Avixgen. In his new role, he intends to continue to make contributions to the company's growth by taking the lead in advancing the pipeline for new drugs and establishing a presence in the North American market.
Board Change • Apr 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
